1 – 57 of 57
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Treating Life-Threatening Bleedings : Development of Recombinant Coagulation Factor VIIa
2017)(
- Book/Report › Book
- 2015
-
Mark
Recombinant activated factor VII: 30 years of research and innovation.
(
- Contribution to journal › Scientific review
- 2014
-
Mark
Joint disease, the hallmark of haemophilia: What issues and challenges remain despite the development of effective therapies?
(
- Contribution to journal › Scientific review
- 2013
-
Mark
Progressive improvement in wound healing with increased therapy in haemophilia B mice
(
- Contribution to journal › Article
- 2012
-
Mark
Factor VIIa binding to endothelial cell protein C receptor: Differences between mouse and human systems
(
- Contribution to journal › Article
-
Mark
Analyses of recombinant activated factor VII treatments from clinical practice for rapid bleeding and acute pain control in haemophilia patients with inhibitors
(
- Contribution to journal › Letter
-
Mark
Activated factor VII: my story.
(
- Contribution to journal › Article
-
Mark
FVIIa as therapeutic agent in hemophilia and beyond.
(
- Contribution to journal › Article
-
Mark
Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa.
(
- Contribution to journal › Article
-
Mark
Influence of endothelial cell protein C receptor on plasma clearance of factor VIIa.
(
- Contribution to journal › Letter
- 2011
-
Mark
Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following IV administration in haemophilia patients.
(
- Contribution to journal › Article
-
Mark
Redistribution and Hemostatic Action of Recombinant Activated Factor VII Associated with Platelets
(
- Contribution to journal › Article
-
Mark
Monitoring rFVIIa 90 μg kg(-1) dosing in haemophiliacs: comparing laboratory response using various whole blood assays over 6 h.
(
- Contribution to journal › Article
-
Mark
Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
(
- Contribution to journal › Article
-
Mark
First 20 years with recombinant FVIIa (NovoSeven).
(
- Contribution to journal › Article
-
Mark
Joint protection in haemophilia
(
- Contribution to journal › Article
- 2010
-
Mark
10th anniversary of the haemophilia/haemostasis Novo Nordisk symposium
(
- Chapter in Book/Report/Conference proceeding › Preface to conference proceeding
-
Mark
Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa)
(
- Contribution to journal › Article
-
Mark
rFVIIa transported from the blood stream into tissues is functionally active
(
- Contribution to journal › Letter
-
Mark
Reply to 'Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors' (Haemophilia 2009; 15: 3-10).
(
- Contribution to journal › Article
-
Mark
History of rFVIIa therapy.
(
- Contribution to journal › Article
- 2009
-
Mark
Bio-Distribution of Recombinant Factor VIIa: A Possible Explanation for the Hemostatic Effect of rFVIIa in Prophylaxis
(
- Contribution to journal › Published meeting abstract
-
Mark
Fibrin gel structure obtained with a FVIIa analogue with enhanced FX-activating potential in haemophilia
(
- Contribution to journal › Letter
-
Mark
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic
(
- Contribution to journal › Article
- 2008
-
Mark
Recombinant human factor VIIa and a factor VIIa-analogue reduces heparin and low molecular weight heparin (LMWH)-induced bleeding in rats
(
- Contribution to journal › Article
-
Mark
Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis.
(
- Contribution to journal › Scientific review
-
Mark
Prevention of haemophilic arthropathy during childhood. May common orthopaedic management be extrapolated from patients without inhibitors to patients with inhibitors?
(
- Contribution to journal › Article
-
Mark
Prevention of arthropathy: may it be extrapolated from patients without inhibitors to patients with inhibitors?
(
- Contribution to journal › Article
-
Mark
FactorVIIa and its potential therapeutic use in bleeding-associated pathologies
(
- Contribution to journal › Article
- 2007
-
Mark
Recombinant factor VIIa (rFVIIa): its potential role as a hemostatic agent
(
- Contribution to journal › Scientific review
-
Mark
Recombinant factor VIIa: its background, development and clinical use.
(
- Contribution to journal › Article
- 2006
-
Mark
Potential role of rFVIIa in prophylaxis in severe haemophilia patients with inhibitors.
(
- Contribution to journal › Article
-
Mark
Mechanism of action of factor VIIa in the treatment of coagulopathies.
(
- Contribution to journal › Article
-
Mark
Mechanism of action of recombinant activated factor VII: An update
(
- Contribution to journal › Article
-
Mark
Mechanism of action, development and clinical experience of recombinant FVIIa.
(
- Contribution to journal › Article
- 2005
-
Mark
The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia
(
- Contribution to journal › Article
- 2004
-
Mark
Recombinant FVIIa.
(
- Contribution to journal › Article
- 2003
-
Mark
The role of recombinant factor VIIa(FVIIa) in fibrin structure in the absence of FVIII/FIX
(
- Contribution to journal › Article
-
Mark
Potential role of recombinant factor VIIa as a hemostatic agent.
(
- Contribution to journal › Article
- 2002
-
Mark
The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries.
(
- Contribution to journal › Article
- 2001
-
Mark
Anti- and procoagulant activities in factor VII-deficient subjects
(
- Contribution to journal › Article
- 2000
-
Mark
Correlation between different intensities of anti-vitamin K treatment and coagulation parameters
(
- Contribution to journal › Article
- 1998
-
Mark
Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model
(
- Contribution to journal › Article
- 1996
-
Mark
Pharmacokinetics and delayed experimental anti-thrombotic effect of two domain non-glycosylated tissue factor pathway inhibitor
(
- Contribution to journal › Article
-
Mark
Does glycosylation influence the experimental antithrombotic effect of a two-domain tissue factor pathway inhibitor?
(
- Contribution to journal › Article
-
Mark
Experimental haemorrhagic effect of two-domain non-glycosylated tissue factor pathway inhibitor compared to low molecular weight heparin
(
- Contribution to journal › Article
- 1994
-
Mark
Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin(TM)). An experimental investigation in healthy volunteers
(
- Contribution to journal › Article
-
Mark
Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis : A comparison with low molecular weight heparin
(
- Contribution to journal › Article
- 1993
-
Mark
Tissue factor pathway inhibitor (TFPI) and its response to heparin in patients with spontaneous deep vein thrombosis
(
- Contribution to journal › Article
- 1990
-
Mark
Effects of low molecular weight heparin and unfragmented heparin on induction of osteoporosis in rats
(
- Contribution to journal › Article
-
Mark
Low molecular weight heparin compared with dextran as prophylaxis against thrombosis after total hip replacement
(
- Contribution to journal › Article
- 1989
-
Mark
Influence of a low molecular weight heparin on the inhibition of factor Xa and thrombin in hip surgery
(
- Contribution to journal › Article
-
Mark
Recurrent thromboembolism in pregnancy and puerperium. Is there a need for thromboprophylaxis?
(
- Contribution to journal › Article
- 1988
-
Mark
Safety and efficacy of a low molecular weight heparin (Logiparin) versus dextran as prophylaxis against thrombosis after total hip replacement
(
- Contribution to journal › Article
- 1987
-
Mark
Effects of an enzymatically depolymerized heparin as compared with conventional heparin in healthy volunteers
(
- Contribution to journal › Article
- 1986
-
Mark
Heparin-induced osteoporosis in rats
(
- Contribution to journal › Article
- 1985
-
Mark
Polymorphism of normal factor IX detected by mouse monoclonal antibodies
1985) In Proceedings of the National Academy of Sciences of the United States of America 82(11). p.3839-3843(
- Contribution to journal › Article